Proteus Biomedical Announces Appointment of David Lawrence as Director
Proteus Biomedical Inc., a pioneer in intelligent medicine, announced today that David Lawrence, M.D. has been appointed to serve on its pharmaceutical systems divisional Board of Directors. Dr. Lawrence joins a distinguished group of independent directors at Proteus that includes Frank Fischer, Ginger Graham, Alan Levy, Kathy Bang and Ben Pless.
“David brings extensive health care delivery, medical technology and health policy experience to Proteus,” said Andrew Thompson, Proteus’ chief executive officer. “David’s perspective on how we best position and launch Proteus products with regulators, health systems, payers and commercial partners will be invaluable.”
Dr. Lawrence was previously the chairman and chief executive officer of Kaiser Foundation Health Plan Inc. and Kaiser Foundation Hospitals. He presently serves on the boards of Agilent Technologies, McKesson Corporation, and Dynavax. He also serves on the RAND Health Advisory Board.
Proteus has developed a pharmaceutical product platform to personalize, monitor and manage medication ingestion and physiologic drug response based on novel formulations of existing pharmaceutical products. The first of these products, focused on cardiovascular disease, tuberculosis and psychiatric disorders, are currently in clinical investigation.
Dr. Lawrence commented, “The ability to personalize medications and make them fit well into the daily lives and therapeutic needs of consumers is a great unmet medical need. Proteus has a compelling product solution and I am delighted to be involved and work with the Proteus team to bring these intelligent medicine products to market.”
About Proteus Biomedical
Proteus Biomedical is pioneering intelligent medicine, an emerging field of advanced therapeutics that integrates in-body computer, sensor and communications technologies into existing medical device, pharmaceutical and hospital products. Proteus’ proprietary computing and sensing technologies enable proven therapies to be personalized, offering broad potential benefits across a range of care settings and therapeutic areas, including cardiovascular, psychiatric, metabolic and neurologic disorders. The company’s first products, novel pacing and sensor-enabled devices for Cardiac Resynchronization Therapy, are in development in collaboration with two world leaders in cardiovascular implantable devices.
More information about Proteus Biomedical can be found at www.proteusbiomed.com.